‘Molnupiravir’, COVID-19 oral drug was successful when administered up to 12 hours before or after the SARS-CoV-2 outbreak
‘Molnupiravir’, an oral antiviral drug is good news for Indians. The spike in the corona cases and death tool has feared the nation. Here is what you will need to know about what, how does the drug work,
As per new research, ‘Molnupiravir,’ an antiviral drug intended to treat influenza, will help decrease corona levels in hamsters. The oral drug is in the final stages of human trials, carrying out the possibility of a pill to curb COVID-19.
What is the ‘Molnupiravir’ drug?
MK-4482, also known as Molnupiravir, was found to be successful when taken up to 12 hours before or after infection with SARS-CoV-2, the novel coronavirus that triggers COVID-19, according to researchers from the National Institutes of Health (NIH) in the United States and the University of Plymouth in the United Kingdom.
As per the study, when studied on hamsters, the procedure would also decrease lung damage.
The study, which is published in the journal Nature Communications on April 16, indicates that MK-4482 therapy could reduce high-risk SARS-CoV-2 exposure and can be used to treat known SARS-CoV-2 alone or together with other agents.
According to the researchers, there are currently no treatments available for high-risk exposure being used against SARS-CoV-2.
How does the Molnupiravir work?
In comparison to SARS-CoV-2 vaccines, few medicines are safe against the virus. According to Michael Jarvis, associate professor of Virology and Immunology at the University of Plymouth and a guest researcher at the NIH, “this is an exciting finding that establishes MK-4482 as a potential antiviral against SARS-CoV-2.”
The COVID-19 oral drug, also known as Molnupiravir, is nearing the end of human clinical trials in SARS-CoV-2 patients.
If human data shows a similar antiviral effect, it may be suitable for use as an orally administered pill following exposure to the virus, similar to the way Tamiflu is used for influenza, the researchers said.
What does that study say?
For three days, the scientists gave MK-4482 or ‘Molnupiravir’ orally to the two therapy groups every 12 hours.
According to their findings, the animals in each care group had 100 times fewer infectious virus in their lungs than the control group.
According to the researchers, animals in the two treatment groups have considerably fewer harm or tissue injury in the lungs than the control group.
Research and Results
Molnupiravir has been shown in human patients to suppress the replication of other associated human coronaviruses, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
Previously, the team had confirmed the drug’s essential action on SARS-CoV-2 replication in human lung cells in the lab.
According to the researchers, along with low cellular toxicity, the procedure resulted in a substantial drop in SARS-CoV-2 replication as opposed to no-drug samples.
Who discovered the drug?
The treatment of the SARS-CoV-2 virus with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, totally inhibits virus transmission within 24 hours, according to the study.
As per the research, which was published in the journal Nature Microbiology, the Georgia State University (GSU) research team found that the drug is effective against influenza viruses.
Why is the drug the need for the hour in India?
An increase in COVID-19 cases in India’s second wave hits 314,835 new coronavirus infections as of April 22 rising to 15,930,965 in total as per MoHFW.
India is the first country to have 3,00,000 cases within just 24 hours. The nation is also facing an oxygen shortage and a poor health care system. In just one day country witnessed 2,104 deaths and has 2.3 million active cases.
In India, the world’s biggest vaccine producer, millions of people are waiting for Covid-19 vaccines amid a devastating second wave of infections.
India manufactures more than 60% of all vaccines marketed globally and the world’s largest vaccine manufacturer, the Serum Institute of India (SII).
Because of its extensive production capabilities, the nation agreed to participate as a major participant in COVAX, a multinational vaccine-sharing program that delivers reduced or free doses to low-income nations.
SII will supply up to 200 million doses for up to 92 countries under the original deal announced last year.
‘Molnupiravir’ – COVID-19 oral drug
After the second wave hit India as a storm has led to a shortage in the vaccine. The new research on Molnupiravir, an antiviral oral drug will help India to fight against the novel coronavirus as it will be in an oral format and can be accessible to everyone.
During the spike in cases and shortage in the vaccines, oxygen and any other medical support, ‘Molnupiravir’, oral drug can make a difference and may work positively.